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Heat Shock Proteins Come of Age: Review
Primitive Functions Acquire New
Roles in an Adaptive World
Cross-reactive protection was observed in some studies
but, with notable exceptions (e.g., Donawho and Kripke,
1990; Frey and Cestari, 1995), such immunity was sub-
stantially weaker than the individually specific immunity
(Coggin and Anderson, 1974).
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specific antigens, the philosophers' stones of cancerFarmington, Connecticut 06030-1601
immunology. In early approaches, cancers and their nor-
mal counterparts were analyzed by high resolution elec-Quae medicamenta non sanat, ferrum sanat. Quae fer-
rum non sanat, ignis sanat. Quae vero ignis non sanat, trophoretic methods to identify cancer-specific bands or
spots. Extensive studies with antibodies, first polyclonalinsanabilia reportari oportet.
(That which drugs fail to cure, the scalpel can cure. That and then monoclonal, scanned the surfaces of human
and mouse cancer cells to define cancer-specific anti-which the scalpel fails to cure, heat can cure. If the heat
cannot cure, it must be determined to be incurable.) gens (Old, 1981). While these studies were immensely
productive in definition of the composition of the mam-ÐHippocrates
malian cell surface and helped identify a number of im-
portant molecules, no truly cancer-specific molecules
were uncovered as a result of this effort. Identification ofSomebody inadvertently turned up the temperature of
cancer-specific molecules recognized by T lymphocytesan incubator over 35 years ago, and the salivary gland
did not come into vogue until recently (Monach et al.,chromosomes of Drosophila melanogaster, thus heat
1995; Boon and van der Bruggen, 1996), because meth-shocked, showed the characteristic puffs indicative of
ods for doing so were previously unavailable. With fewtranscriptional activity at discrete loci (Ritossa, 1962).
exceptions (Coulie et al., 1995; Monach et al., 1995;These heat shock loci encoding the heat shock proteins
Robbins et al., 1996) these studies, too, have generally(HSPs) became in subsequent years absorbing models
identified molecules shared between cancers and nor-for the study of transcriptional regulation, stress re-
mal tissues.sponse, and evolution. Collectively, the HSPs constitute
Another approach to the problem was to look for thethe most abundant group of molecules in living forms.
cancer-specific antigens by their ability to elicit protec-While expression of HSPs may be induced by heat
tive immunity to cancer challenges, i.e., by the veryshock, glucose deprivation, and other stresses, most
HSPs are present in abundant levels even under normal
conditions (reviewed by Lindquist and Craig, 1988). Re-
cent years have seen the emergence of compelling evi-
dence that HSPs possess unique properties that permit
their use in generating specific immune responses
against cancers and infectious agents; these applica-
tions suggest a critical role for HSPs in adaptive and
innate immunity in vivo and raise the possibility that
the HSPs are the primordial molecules involved in host
defense.
Purified Heat Shock Protein Preparations
Elicit Protective Immunity to a Diverse
Array of Cancers
Inbred mice immunized with irradiated syngeneic cancer
cells were observed, as early as 1943, to be resistant
to subsequent challenges with the cancer cells used for
immunization (reviewed by Srivastava and Old, 1988).
These experiments generated two tenets. (1) Cancers
are immunogenic in syngeneic hosts. This was con-
firmed for cancers of a wide variety, including those
induced by chemicals and UV radiation and for sponta-
neous cancers as well. (2) Immunity to cancer is specific
Figure 1. Individually Distinct Immunogenicity of Cancersfor each individual cancer (Figure 1). Mice were best
Immunization with a particular cancer elicits the most potent protec-protected from challenge only with the specific cancer
tive immunity to the specific cancer used for immunization andthat was used to immunize. Thus, the cancer antigens
not to other cancers, even if the tumors are induced by the samewere not cancer specific nor cancer-type specific (e.g.,
carcinogen and are of the same histological origin (see Gross, 1943;
hepatoma specific), but they were individually specific. Prehn and Main, 1957; Klein et al., 1960; Old et al., 1962; Globerson
and Feldman, 1964; Basombro, 1970).




Table 1. Cancer-Derived Proteins which Have Been Shown to Elicit Protective Immunity to Cancers
Cancer Induced by Immunogenicity Host Molecules Assay References
Zajdela hepatocarcinoma Chemical 11 Rat gp100 (gp96) Prophylaxis Srivastava and Das, 1984
Meth A fibrosarcoma Chemical 11 BALB/c mice gp96 Prophylaxis Srivastava et al., 1986
gp96 Therapy Tamura et al., 1997
hsp90 Prophylaxis Ullrich et al., 1986
hsp70 Prophylaxis Udono and Srivastava, 1993
CMS5 Chemical 1 BALB/c mice gp96 Prophylaxis Srivastava et al., 1986
CMS13 Chemical 11 BALB/c mice gp96 Prophylaxis Palladino et al., 1987
Lewis lung carcinoma Spontaneous 2 C57BL/6 mice gp96 Therapy Tamura et al., 1997
hsp70 Therapy Tamura et al., 1997
B16 melanoma Spontaneous 2 C57BL/6 mice gp96 Therapy Tamura et al., 1997
gp96 Therapy Nicchitta, 1998
CT26 Colon carcinoma Chemical 11 BALB/c mice gp96 Therapy Tamura et al., 1997
UV6138 UV 111 C3H mice gp96 Prophylaxis Janetzki et al., 1998
UV6139SJ UV 11 C3H mice gp96 Prophylaxis Janetzki et al., 1998
gp96 Therapy Tamura et al., 1997
assay that pointed to their existence. This approach some credence when a seemingly large collection of
peptides was shown to be associated with apparentlytypically involved fractionation of cancer homogenates
into various protein components by conventional chro- homogeneous gp96 preparations (Li and Srivastava,
1993). Formal proof for the idea came when depletionmatographic methods. The fractions thus obtained were
used to immunize animals that were then challenged of peptides from tumor-protective hsp70 preparations
rendered them ineffective in immunizing against cancerwith live cancer cells. The fractions that elicited protec-
tion against the cancer were then refractionated and the cells (Udono and Srivastava, 1993; Peng et al., 1997).
Recent studies from a number of laboratories havecancer rejection assay repeated until apparently homo-
geneous preparations were obtained. This approach, begun to provide structural support for peptide binding
activity of certain HSPs. The ability of an ER homologwith variations, led to identification of cancer-rejection
molecules from cancers of diverse histological origins, of hsp70, BiP, to bind short stretches of peptides in vitro
was first demonstrated by Flynn et al. (1989). Recently,induced in mice and rats of different haplotypes by
chemicals, UV-radiation, or of spontaneous origin. The Zhu et al. (1996) have shown the presence of a definite
peptide-binding pocket in a bacterial hsp70 molecule.cancers ranged in immunogenicity from the nonimmu-
nogenic (e.g., the Lewis lung carcinoma) to the highly The peptide binding activity of gp96 has also been dem-
onstrated independently (Wearsch and Nicchitta, 1997),immunogenic regressor cancers induced by UV radia-
tion. Surprisingly, all the well-characterized molecules and although the mechanism and the site of peptide
binding by gp96 are yet unknown, studies with fluores-identified by this method turned out to be HSPs of the
hsp90 or the hsp70 family (Table 1), including gp96, cent probes point to the presence of a possible hy-
drophobic peptide-binding pocket (Wearsch et al., 1998).hsp70, and hsp90. The first of the two tenets of cancer
immunity, that cancers elicit protective immunity in syn- The cytosolic homolog of gp96, hsp90, is also being
studied extensively in this regard. Studies of Scheibelgeneic hosts, had thus achieved a molecular definition.
Consistent with tenet two, the HSPs purified from a et al. (1998) suggest the existence of two substrate-
binding sites in hsp90, while ongoing crystal structuregiven cancer were observed toelicit protective immunity
specific to that particular cancer. HSPs derived from studies are in the process of clarifying the identity and
structure of the peptide-binding pocket of hsp90 (Pro-normal tissues did not elicit protective immunity to any
cancers tested (Udono and Srivastava, 1994). The ob- dromou et al., 1997a, 1997b; Stebbins et al., 1997).
The idea of HSPs as chaperones of antigenic peptidesserved specificity of immunogenicity of cancer-derived
HSPs would suggest that they display somatic polymor- has also been strengthened by a series of independent
immunological observations. In the first independentphism such that HSPs would differ between cancers
and normal tissues and from one cancer to another. confirmation of the original observations, Arnold et al.
(1995) showed that immunization of mice with gp96However, extensive sequencing studies of HSP cDNAs
of cancers and normal tissues did not support this idea preparations isolated from cells transfected with the
gene encoding b-galactosidase elicited cytotoxic T lym-(see Srivastava, 1993). What is the origin of the specific-
ity of immunogenicity? phocytes (CTLs) specific for an Ld-restricted epitope
of b-galactosidase. Similarly, immunization with gp96
preparations purified from cells expressing certain mi-Search for Specificity: Discovery
of HSP-Associated Peptides nor histocompatibility antigens elicited CTL responses
against the particular minor antigens. Nieland et al.As the HSP preparations used to immunize were homo-
geneous by all criteria tested, the possibility was envis- (1996) identified a known viral epitope found associated
with gp96 purified from virus-infected cells; such pep-aged that low molecular weight substances not detectable
by polyacrylamide gel electrophoresis are associated tides could not be detected in gp96 preparations from
uninfected cells. Blachere et al. (1997) reconstitutedwith HSPs and are responsible for the specificity of
immunogenicity of HSP preparations (Srivastava and gp96-peptide and hsp70-peptide complexes in vitro and
demonstrated with a large panel of peptides that whileHeike, 1991; Srivastava and Maki, 1991). This idea gained
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the origin of diversity of immunoglobulins (Burnet, 1957;
Lederberg, 1959) and may have a fundamentally similar
solution (Srivastava, 1993). In this view, (i) the immuno-
genicity of cancers results not from one or a few cancer-
specific peptides, but from a large and complex array
of them; (ii) cancer-specific antigens are generated by
random mutations that accumulate in cancers because
of continuous cell division and the genomic instability
of cancers (Cahill et al., 1998)Ðthe mutated peptides
become antigenic by virtue of their presentation (selec-
tion) bythe MHC alleles of the tumor; (iii) the randomness
of the mutational process leads to an individually spe-
cific antigenic fingerprint for each cancer, accounting
for the individually specific immunogenicity of nearly all
cancers tested (Figure 1); and finally, (iv) the mutationalFigure 2. Chaperoning of Peptides by HSPs Is Essential for Immu-
nogenicity repertoire that becomes immunogenic is incidental to
Unchaperoned peptides, or empty HSPs, or peptides associated the transformation process; thus, the transforming mu-
with non-HSP peptide-binding proteins are not immunogenic (see tations such as those in ras, p53, and other such mole-
Blachere et al., 1997). cules do not contribute significantly to the immunoge-
nicity of cancers, which results from other random,
unrelated mutations.
HSPs and peptides were nonimmunogenic by them- While this hypothesis explains the individually distinct
selves, peptides chaperoned by HSPs elicited antigen- antigenicity of cancers and of the HSP-peptide com-
specific CD81 cytotoxic T lymphocytes (CTLs). The plexes derived from them, it is apparently inconsistent
quantity of antigenic peptides associated with an immu- with recent studies where a number of CTL epitopes on
nogenic dose of gp96-peptide complexes was found human melanomas have been identified and found to
to be extremely small (z1±2 nanograms). Significantly, be common to melanomas and normal tissues (Boon
immunogenicity did not result when peptides were com- and Van der Bruggen, 1996). A close look reveals that
plexed with another peptide-binding protein, mouse se- the inconsistency results not from species-specific dif-
rum albumin, suggesting that the ability to elicit CTLs is ferences between mice and men, but from the assays
unique to HSP-chaperoned peptides. Roman and Moreno used to identify the antigens: observations on murine
(1996, 1997) showed that peptides complexed with a cancers are based on cancer rejection assays in vivo,
xenogeneic (mycobacterial) hsp70 could also elicit pep- while studies with human melanomas are, of necessity,
tide-specific CD41 T cells in mice. based on CTL assays in vitro, which do not distinguish
These studies support the two original observations: between an active response in vivo and an inactive re-
(1) HSP preparations isolated from cells are associated sponse in vivo that is expandable in vitro because of
with a large repertoire of peptides, including antigenic lack of regulatory constraints (see Srivastava, 1996, for
peptides; and (2) HSP-peptide complexes isolated from full discussion). Indeed, when murine cancer antigens
intact cancer cells or virus-infected cells or reconsti- are examined by CTL assays in vitro, common CTL epi-
tuted in vitro with antigenic peptides are immunogenic topes are readily detected (Rohrer et al., 1994), as in
(Figure 2). These observations demonstrated the HSPs human melanomas (Boon and van der Bruggen, 1996).
to be the first adjuvants of mammalian origin (Blachere However, there is little evidence thus far that the known
et al., 1997). unmutated CTL epitopes of human cancers are immuno-
protective. Studies with unmutated CTL epitopes of mu-
HSP-Peptide Complexes for Immunotherapy rine cancers show that while such epitopes elicit CD81
of Cancers CTL responses as measured in vitro, immunization with
The observation that the immunogenicity of HSP prepa- the unmutated peptides does not lead to protection
rations from a large variety of cancers (Table 1) actually against a tumor challenge in vivo (Ramarathinam et al.,
originated from bound peptides returned the spotlight 1994; Huang et al., 1996).
to the identity of the cancer-specific antigens. Which Mutated CTL epitopes have also been identified on
of the HSP-bound peptides are unique to cancer and human cancers (Coulie et al., 1995; Wolfel et al., 1995;
therefore immunogenic? The chromatographic profiles Boon and van der Bruggen, 1996; Robbins et al., 1996).
of peptides eluted from HSP preparations (as well as Based on experience with murine cancers (Mandelboim
MHC class I preparations) of cancers and normal tissues et al., 1995; Monach et al., 1995), the mutated human
are very much alike, and it is impossible to identify the cancer epitopes would be expected to elicit protective
cancer-specific peaks in an overwhelming background immunity. However, such epitopes are expressed spe-
of common peptides. The problem is compounded by cifically on single individual cancers or a small number
the individual antigenic specificity of cancers (Figure 1), of cancers and are therefore inappropriate for general
which would indicate that the antigen(s) identified for a use; further, identification of mutated epitopes on indi-
given cancer must be different from those for another vidual human cancers is daunting and impractical. The
cancer. The seemingly unlimiteddiversity of cancer anti- use of cancer-derived HSP-peptide complexes, which
gens, viewed in the context of the limited size of the appear to elicit immunity to the entire array of epitopes
of the cancers from which they are isolated, circumventsgenome, is reminiscent of the early questions regarding
Immunity
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this dilemma; such complexes can be readily isolated or hsp70 and peptides could be used to elicit potent
from cancers without need of prior identification of the and specific anti-peptide antibodies without the use of
epitopes from individual cancers and have been shown additional adjuvants. The responses were shown to be
to be effective in treatment of preexisting primary and T cell dependent. Vaccination with noncovalent myco-
micrometastatic disease (Tamura et al., 1997; Nicchitta, bacterial hsp70-peptide complexes has also been shown
1998). Clearly, appropriatelycontrolled clinical trials with to elicit anti-peptide CD41 T cells (Roman and Moreno,
defined unmutated CTL epitopes common to cancers 1996); CD81 responses were not tested in this study.
and with HSP-chaperoned naturallyprocessed epitopes In an interesting variation on this general theme, CTL
specific for individual cancers will resolve if the reper- responses and T cell-dependent protective immunity
toire of protective human cancer antigens is individually have been elicited recently by immunization of mice
distinct, or shared between cancers. with a mycobacterial hsp70-ovalbumin fusion protein
(Suzue et al., 1997). Several new facts emerge from
HSP-Peptide Complexes for Therapy of Infectious these studies, as also new questions emerge. Clearly,
Diseases: HSPs as Agents of Cross-Priming these studies show that immunization with HSP-peptide
and as Adjuvants complexes can elicit not only CTL but also antibody
It was suggested in 1991 (Srivastava and Maki, 1991) responses. Whether this is a unique property of covalent
that if HSPs chaperone a substantial proportion of the HSP-peptide complexes is unclear, since the ability of
antigenic repertoire, immunization with HSP-peptide noncovalent HSP-peptide complexes to elicit such anti-
complexes derived from virus-transformed or infected peptide antibodies has not been tested. It further re-
cells should elicit viral immunity. Subsequently, gp96 mains to be determined whether covalent complexes of
preparations isolated from SV40-transformed cells were syngeneic HSPs with peptides will be effective in elic-
shown to elicit specific, MHC I±restricted CTL response iting anti-peptide antibodies in mice, or whether the
(Blachere et al., 1993). Similar results were obtained in xenogeneicity of the mycobacterial HSPs makes them
the influenza system by Heikema et al. (1997) with gp96 particularly able to do so. Finally, the observation that
purified from influenza-infected cells. Recently, immu- fusion proteins incorporating mycobacterial hsp70 and
nization of mice with gp96 or hsp70 molecules reconsti- a relevant antigen elicit protective T cell response sug-
tuted with specific CTL epitopes derived from SV40, gests that syngeneicity of the HSPs may not be generally
influenza virus, vescicular stromatitis virus (VSV), and essential for chaperoning of peptides leading to a pro-
lymphocytic choriomeningitis virus (LCMV) has been ductive CD81 T cell response.
shown to elicit cognate virus-specific CTL responses The immunogenicity of HSP-peptide complexes has
(Suto and Srivastava, 1995; Blachere et al., 1997; Ciupitu a number of significant implications for vaccination
et al., 1998). In the case of LCMV, Ciupitu et al. (1998) against intracellular infections and treatment of preex-
showed that mice immunized with hsp70 molecules isting infections including viruses, mycobacteria, and
mixed with a known 8-mer kb MHC I binding epitope certain parasites. Such vaccination does not require
were also protected against subsequent LCMV in- identification of immunogenic epitopes or attenuation
fection. of the agents normally required to create vaccines. As
HSPs are nonpolymorphic; that is, individual HSP immunization with HSP-peptide complexes derived from
genes do not have more than one allele. It was therefore infected cells is directed against the entire antigenic
reasoned that HSP preparations isolated from cells in- repertoire, it drastically reduces, if not eliminates, the
fected with a given virus should contain the same reper- possibility of development of escape variants. Should
toire of peptides regardless of the MHC haplotype of vaccination against a new variant be necessary, as in
the cells. Hence, HSP preparations isolated from virus- the case of certain highly mutable infectious agents,
infected cells of one haplotype should be able to prime
creation of a vaccine against the new variant depends
antiviral response in mice of another haplotype (Srivas-
only on its isolation and does not require its character-
tava et al., 1994), a phenomenon known as cross-prim-
ization. Further, as cancer-derived HSP-peptide com-
ing (Bevan, 1976). This was shown in the case of VSV,
plexes have been used to elicit regression, even cureas gp96 preparations from VSV-infected cells of the b
of preexisting cancers, a reasonable case can be madeor the d haplotype were equally effective in eliciting
that HSP-peptide complexes from infected cells may beb-haplotype specific, antigen-specific anti-VSV CTLs
used not only for prophylaxis against infections, but also(Suto and Srivastava, 1995). At the same time, Arnold
for therapy of chronic infections.et al. (1995) demonstrated the ability of gp96 prepara-
The adjuvanticity of mammalian HSPs is unique intions to cross-prime CTL responses in the case of minor
many respects (Blachere et al., 1997). They are the firsthistocompatibility antigens. The ability of HSP-peptide
and, thus far, the only adjuvants of mammalian origin.complexes to cross-prime is significant from the van-
Being self antigens, they do not elicit an immune re-tage point of their potential use as vaccines against
sponse to themselves. They are non-live, and yet theyintracellular infections where CD81 responses are pro-
elicit CD81 T cell responses in addition to antibody re-tective.
sponses, and finally, their apparent promiscuity in pep-In addition to the studies with syngeneic (i.e., mouse)
tide-binding makes them applicable to a wide variety ofHSPs, a number of interesting observations have been
antigens. These properties are particularly interesting inmade with the mycobacterial HSP-peptide complexes.
light of the paucity of adjuvants judged to be effectiveLussow et al. (1991) and Barrios et al. (1992) first ob-
served that covalent complexes of mycobacterial hsp65 and safe for human use.
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A Relay Line of Chaperones in Antigen Presentation 1997). In light of the accumulating evidence of physical
association of an increasing number of molecules in-As the broad outlines of antigen presentation by MHC
Imolecules have emerged over the lastdecade, it isclear volved in antigen presentation by MHC I molecules (see,
for example, Monaco, 1992; Tsubuki et al., 1994; Noss-that peptides traffic from the cytosol to the endoplasmic
reticulum (ER). However, aqueous lysates of cells do ner and Parham, 1995; Williams and Watts, 1995; Sada-
sivan et al., 1996; Ortmann et al., 1997; Hughes andnot reveal the presence of significant quantities of rele-
vant free peptides. In this context, the observation that Cresswell 1998; Lindquist et al., 1998), we propose here
a modification of the relay line model and suggest thatHSPs, the most abundant proteins of the cytosol and
the ER, are associated with a broad array of peptides the transfer of peptides to MHC I molecules occurs in
an organized milieu that extends on both sides of theled us to suggest that the peptides do not simply diffuse
to the transporters associated with antigen processing ER membrane. We name this putative milieu as a pre-
sentosome. It is suggested that the successful transfer(TAP) in the cytosol, nor from TAP to MHC I molecules
in the ER, but they are chaperoned by hsp70 and hsp90 of peptides from the point of their generation to their
being loaded on MHC I molecules is coordinated andmolecules in the cytosol and gp96 molecules in the ER
(Srivastava et al., 1994). While the observation that TAP regulated by a number of molecules whose physical
vicinity to each other and spatial interaction with eachmolecules associate directly with certain MHC I alleles
(Ortmann et al., 1994) would suggest that intermediary other is essential for an orderly transfer and processing
of peptides. HSPs constitute key components of themolecules are not required for transfer of peptides from
TAP to MHC I, it is clear that even alleles that do not presentosome. The association of hsp90 and hsp70 with
the progesterone receptor and the role of the HSPsassociate with TAP can be charged with peptides effi-
ciently (Neisig et al., 1996). The direct association of in activation of the progesterone receptor is a useful
precedent in this regard (Pratt and Toft, 1997). The sug-certain MHC I alleles with TAP therefore does not, in and
of itself, argue against the relay line model. A number of gestion for existence of a new multimolecular assembly
is fraught with academic danger; however, contempla-recent observations are consistent with the relay line
model. Peptides transported through TAP have been tion of broad biochemical principles and biological prec-
edent and perusal of the emerging evidence on the sub-shown to be associated with gp96 and other ER chaper-
ones including protein disulfide isomerase (Lammert ject compel us to take that risk.
et al., 1997a, 1997b; Marusina et al., 1997; Spee and
Neefjes, 1997). Similarly, other peptide-binding proteins
Mechanisms of Immunogenicityhave been identified on the cytosolic side (Marusina et
of HSP-Peptide Complexesal., 1997). Arnold et al. (1997) have recently shown that
The firstclue into the mechanism through which immuni-gp96 preparations from TAP-defective cells are unable
zation with HSP-peptide complexes elicits antigen-spe-to prime CTL responses for antigens whose presenta-
cific CD81 T cells came from macrophage and T celltion is TAP-dependent, thus establishing a link between
depletion studies in vivo which showed that primingthe TAP-transported antigenic peptides and gp96.While
of immune response by HSP-peptide complexes wasthese observations are consistent with the existence of
exquisitely sensitive to abrogation of function of phago-an obligatory relay line of chaperones in antigen presen-
cytic cells (Udono et al., 1994). Subsequently, it wastation by MHC I molecules, they are insufficient to prove
shown that macrophage but not B cells, fibroblasts,its existence. Traditionally, functional requirements for
or other nonprofessional antigen presenting cells (APC)molecules have been demonstrated by mutations in
take up gp96-peptide complexes and represent thecells or knockout mice; however, the global require-
gp96-chaperoned peptides on the MHC I molecules ofments of chaperones for a wide variety of cellular pro-
the macrophages (Figure 3); representation does notcesses makes it infeasible to generate such reagents.
occur by transfer of peptides from the gp96 moleculesThe use of inducible down-regulation of HSP genes may
to MHC I on the cell surface (Suto and Srivastava, 1995).answer this difficulty.
The observation that extremely small quantities of HSP-In spite of a rapid expansion of our understanding of
peptide complexes were effective in eliciting specificantigen presentation, the questions of the mechanism
immunity led to the suggestion that professional APCsof trafficking of peptides from the point of their genera-
possess HSP-receptors that take up HSP-peptide com-tion in the cytosol to their being loaded on the MHC I
plexes with specificity (Srivastava et al., 1994). Whilemolecules remain unresolved. Examination of a number
it is clear that only the specialized antigen presentingof complex phenomena such as transcription, recombi-
cells can bind and represent HSP-chaperoned peptides,nation, replication, and translocation indicates that al-
structural identity of the putative receptor is presentlythough the central events in each of these processes
unknown. The representation assay suggests that thisinvolve a relatively small number of players, the success-
receptor is not present on unactivated macrophagesful completion of the phenomena requires interplay of a
and is present on a subpopulation of activated macro-surprisingly large number of molecules. As an example,
phages. The representation involves trafficking of thewhile replication may simply be viewed as generation
peptides througha nonacidic compartment and is sensi-of a DNA molecule by interaction of DNA polymerase
tive to brefeldin A (Suto and Srivastava, 1995). Furtherwith nucleotide substrates and a DNA template, the ba-
details of the mechanism, including the identity of thesic process actually involves at least ten core proteins
macrophage compartment that takes up the HSP-pep-and can be further modified by a multitude of accessory
regulatory proteins (reviewed by Hickey and Malkas, tide complexes, the mechanism by which the peptides
Immunity
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when adaptive immune response was but a distant
gleam in the evolutionary eye, the interaction of HSPs
with macrophage-like cells, leading to stimulation of the
macrophage-like cells to secrete IL-1 and othermessen-
gers, was the primary ªinnateº defense mechanism. As
HSPs are the most abundant soluble molecules in cells,
they can be reasonably expected to be the most reliable
messengers of cell death or, at any rate, cell lysis, which
would result if the organism were in stress or danger,
e.g., being consumed by a predator. This chain of events
would also explain the otherwise strange presence of a
surface receptor for HSPs, which are normally intracellu-
lar. In this view, the HSPs would have been transformed
from being protectors of cells from cellular stress in the
single-celled organisms to being messengers of stress
and protectors against such stress in the first multicellu-
lar organisms or, at any rate, among those in which a
differentiated macrophage-like cell had evolved. By all
accounts, this happened quite early, as phagocytes of
echinoderms, mollusks, annelids, and tunicates had al-
ready acquired the ability to secrete IL-1 like molecules
(see Ottaviani and Franceschi, 1997). From this initial
point, it is relatively straightforward to see how the HSP-
Figure 3. HSP-APC Interaction APC interaction could have been incorporated into fu-
ture versions of the developing defense mechanismsInteraction of HSP-peptide complexes with APCs has two conse-
quences: an antigen-specific response due to representation of until, with the arrival of specific immunity and its para-
HSP-chaperoned peptides by the MHC I molecules of APC, subse- phernalia of specificity of peptide-binding and T cell
quently leading to stimulation of cognate T cells (Suto and Srivas- receptors, the primal peptide-binding proteins, i.e., the
tava, 1995), and a nonspecific response in form of stimulation of
HSPs, would become accessories in antigen presenta-APC to release cytokines.
tion by MHC molecules. The evolutionary implications
of a convergence of the peptide-binding functions of
the HSPs and the MHC molecules has been discussedarrive at the ER, the proteasome dependence and TAP
in detail elsewhere (Srivastava and Heike, 1991).dependence of processing and transport, and the fate
In the proposed role of HSPs as harbingers of cell
of the gp96 itself, are still unclear. The mechanism of
death and, therefore, of danger to an organism (see
immunogenicity of other HSP preparations, the hsp90-
Matzinger, 1994), a kind of death that results in an en-
and hsp70-peptide complexes, also remains to be clar-
counter of HSPs with the immune system will be more
ified. productive, i.e., communicative of danger, and protec-
tive than a ªsilent deathº that does not lead to HSP-
HSPs in Innate Immunity: Messengers of Cell APC interaction. It is therefore our belief that immunoge-
Death (Lysis) in Primordial Defense? nicity of cells, infectious agents, and cancers is defined
During the analysis of representation of HSP-peptide to a significant degree upon the extent to which cell
complexes by APCs, another facet of HSP-APC inter- death leads to induction of HSPs and consequent HSP-
action came to light. Exposure of APCs to gp96 prep- APC interaction. Studies that show a cosegregation of
arations was observed to lead to stimulation of APCs immunogenicity of cancers with the expression of mole-
to secrete low levels of cytokines regardless of the cules of the hsp60 and hsp70 family (Menoret et al.,
peptides associated with gp96 (Suto and Srivastava, 1995; Wells et al., 1997; Melcher et al., 1998) are consis-
1995; Figure 3). This was surprising but consistent with tent with this belief. It may be tempting in this context
the observation that immunization with cancer-derived to imagine that immunologically unproductive and pro-
HSP-peptide complexes elicits, in addition to the CD81 ductive modes of death will correlate neatly with apo-
and CD41 T cell response, an NK response that is crucial ptotic and necrotic types of death; however, recent re-
for eliciting protective immunity (Tamura et al., 1997). In sults indicate that this is not necessarily so (Bellone et
al., 1997; Albert et al., 1998; Melcher et al., 1998). Otherlight of the fact that HSPs are abundant components of
factors yet to bediscovered must influence the immuno-pathogens as well as hosts, this observation may indi-
logical productivity of dying cells. In any case, it is safecate a basic role for HSP-APC interaction in innate im-
to suggest that the recent fascination of immunologistsmunity in addition to the crucial role of such interactions
with death has atavistic origins in the evolutionary past,in adaptive, peptide-dependent immunity discussed
when the presence of extracellular HSPs signaled physi-thus far (Srivastava et al., 1994; Udono et al., 1994; Suto
cal disintegration.and Srivastava, 1995). Contemplation of these ideas
leads to some interesting insights. HSPs are among the
Referencesmost primitive proteins in living systems, and macro-
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CTLs. Nature 392, 86±89.1996). It is conceivable that in a less polymorphic era,
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